IP Library Patent Application 17725255
Patent Application
App. No. 17/725,255

CELL SUSPENSION COMPOSITION WITH THERAPEUTIC POTENTIAL AND RELATED METHODS AND SYSTEMS FOR IDENTIFYING SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/725,255
Abstract

Systems and methods for identifying a cell suspension with therapeutic potential for skin regeneration and related compositions are disclosed herein. In some variations, a method may include receiving a cell suspension that comprises a population of viable cells and non-viable cells, then measuring a value indicative of at least one characteristic of the cell suspension, such as but not limited to one or more of total cell count, total cell viability, cell viability percentage, and median live cell diameter. A cell suspension composition having therapeutic potential may comprise a cell suspension met certain thresholds relating to total cell count, total viable cell count, cell viability percentage, and median live cell diameter.

Claims (16)

1 . A cell suspension, comprising:

a population of cells derived from freshly disaggregated tissue, comprising at least 550,000 total cells per milliliter, wherein the population of cells has at least 30% viability, wherein at least 300,000 cells are viable, and wherein the median live cell diameter of the viable cells is greater than or equal to 9 micrometers; and

an effective amount of buffer.

2 . The cell suspension of claim 1 , wherein the tissue comprises skin tissue.

3 . The cell suspension of claim 2 , wherein the population of cells comprises keratinocytes, melanocytes, and fibroblasts.

4 . The cell suspension of claim 1 , wherein the population of cells is obtained by a process comprising:

obtaining a split-thickness skin sample;

contacting the epidermal sample with an effective amount of warmed enzyme solution;

contacting the epidermal sample with an effective amount of buffer;

mechanically disaggregating the epidermal sample;

contacting the epidermal sample with a second effective amount of buffer to create a buffered disaggregated tissue solution; and

passing the buffered disaggregated tissue solution through a filter, wherein the screen is at least as narrow as 100 micrometers.

6 . A cell suspension therapeutic, comprising:

a population of cells derived from freshly disaggregated tissue, comprising at least 550,000 total cells per milliliter, wherein the population of cells has at least 30% viability, wherein at least 300,000 cells are viable, and wherein the median live cell diameter of the viable cells is greater than or equal to 9 micrometers;

an effective amount of buffer; and

at least one scaffolding element.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jan 14, 2026
From: ORCO IV LLC
To: AVITA MEDICAL, INC.
Reel/Frame 073473/0645 →
SECURITY INTEREST Recorded Jan 13, 2026
From: AVITA MEDICAL, INC.; AVITA MEDICAL AMERICAS, LLC
To: PERCEPTIVE CREDIT HOLDINGS V, LP
Reel/Frame 073458/0492 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 29, 2024
From: AVITA MEDICAL AMERICAS, LLC
To: AVITA MEDICAL, INC.
Reel/Frame 068115/0149 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2024
From: AVITA MEDICAL, INC.
To: AVITA MEDICAL AMERICAS, LLC
Reel/Frame 068115/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2024
From: BUSH, KATIE; DOSHI, NIRAJ KUMAR; HOPKIN, AMELIA RUTH; ALTMAN, BRIANA RACHEL LEE
To: AVITA MEDICAL AMERICAS, LLC
Reel/Frame 068115/0229 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 29, 2024
From: AVITA MEDICAL PTY LIMITED
To: AVITA MEDICAL, INC.
Reel/Frame 068115/0140 →
SECURITY INTEREST Recorded Oct 18, 2023
From: AVITA MEDICAL, INC.
To: ORCO IV LLC
Reel/Frame 065262/0133 →